638219-77-9

Basic information

• Product Name: 5-Bromo-N-cyclopropylpyridine-2-carboxamide
• Synonyms: 5-Bromo-N-cyclopropylpicolinamide;5-Bromo-N-cyclopropylpyridine-2-carboxamide;N-Cyclopropyl 5-bromopicolinamide;N-cyclopropyl 5-bromopyridine-2-carboxamide
• CAS NO: 638219-77-9
• Molecular Formula: C9H9BrN2O
• Molecular Weight: 241.08
• Product Categories: blocks;Bromides;Carboxes;Pyridines
• Mol File: 638219-77-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 389.5ºC at 760 mmHg
• Flash Point: 189.4ºC
• Appearance: /
• Density: 1.62g/cm3
• Vapor Pressure: 2.83E-06mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: 2-8°C
• PKA: 13.24±0.20(Predicted)
• CAS DataBase Reference: 5-Bromo-N-cyclopropylpyridine-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-N-cyclopropylpyridine-2-carboxamide(638219-77-9)
• EPA Substance Registry System: 5-Bromo-N-cyclopropylpyridine-2-carboxamide(638219-77-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 638219-77-9(Hazardous Substances Data)

Usage

General Description

5-Bromo-N-cyclopropylpyridine-2-carboxamide is a chemical compound with the molecular formula C9H8BrN3O. It is a pyridine derivative with a cyclopropyl group and a bromine atom attached to the nitrogen and carbon atoms, respectively. 5-Bromo-N-cyclopropylpyridine-2-carboxamide is used in medicinal chemistry as a potential building block for drug development, particularly in the synthesis of pharmaceuticals and agrochemicals. It may also have biological activities and applications in research and development. The specific properties and uses of 5-Bromo-N-cyclopropylpyridine-2-carboxamide make it a valuable compound with potential applications in various fields of chemistry and pharmaceutical science.

InChI:InChI=1/C9H9BrN2O/c10-6-1-4-8(11-5-6)9(13)12-7-2-3-7/h1,4-5,7H,2-3H2,(H,12,13)

Upstream product

• 30766-11-1 5-bromoisonicotinic acid 
• 765-30-0 Cyclopropylamine 
• 137178-88-2 5-bromopyridine-2-carbonyl chloride 

Downstream Products

• 638219-79-1 5-bromo-1-oxy-pyridine-2-carboxylic acid cyclopropylamide 

Relevant articles and documents

Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT

Herein, we report two promising compounds 30 and 36 possessing nanomolar FLT3 inhibitory activities (IC50 = 1.5-7.2 nM), high selectivity over c-KIT (>1000-fold), and excellent anti-AML activity (MV4-11 IC50 = 0.8-3.2 nM). Furthermore, these two compounds efficiently inhibited the growth of multiple mutant BaF3 cells expressing FLT3-ITD, FLT3-D835V/F, FLT3-F691L, FLT3-ITD-F691L, and FLT3-ITD-D835Y. Oral administration of 30 and 36 at 6 mg/kg/d could significantly suppress tumor growth in the MV4-11 cell-inoculated xenograft model, exhibiting tumor growth inhibitory rates of 83.5% and 95.1%, respectively. Importantly, 36 could prolong the mouse survival time in the FLT3-ITD-TKD dual mutation syngeneic mouse model (BaF3-FLT3-ITD-D835Y) at a dose of 6 mg/kg p.o. bid/4W. No clear myelosuppression was observed in the treated group of 36 in the MPO strain of zebrafish, even at 10 μM. In summary, our data demonstrated that 36 may represent a promising candidate for the treatment of FLT3 mutant AML.

Design, synthesis, and biological evaluation of 8-biarylquinolines: A novel class of PDE4 inhibitors

The structure-activity relationship of a novel series of 8-biarylquinolines acting as type 4 phosphodiesterase (PDE4) inhibitors is described herein. Prototypical compounds from this series are potent and non-selective inhibitors of the four distinct PDE4 (IC50 50 0.5 μM) the LPS-induced release of the cytokine TNF-α. Optimized inhibitors were evaluated in vivo for efficacy in an ovalbumin-induced bronchoconstriction model in conscious guinea pigs. Their propensity to produce an emetic response was evaluated by performing pharmacokinetic studies in squirrel monkeys. This work has led to the identification of several compounds with excellent in vitro and in vivo profiles, including a good therapeutic window of efficacy over emesis.